Lunai Bioworks plans Nasdaq delisting after listing compliance notice
Lunai Bioworks says Nasdaq notified it that the company no longer complies with listing requirements, and it intends to delist and deregister. The move creates a transition from exchange-listed trading to an unlisted market while the company addresses its compliance position.
PR NEWSWIRE / FILEThe story
Lunai Bioworks said it received a letter from Nasdaq’s Listing Qualifications Department on October 21, 2026, stating that the company no longer complies with Nasdaq listing requirements. The company announced the determination on October 22 and said it intends to voluntarily delist from Nasdaq and deregister its securities.
The announcement follows a period in which Lunai reported fiscal-year revenue of $51,992 for the year ended June 30, 2026, up 58.7% from the prior year. Its reported net margin was -6852.0%, with diluted EPS of $-1.06.
The Nasdaq determination directly affects LNAI’s exchange listing and the market in which its shares trade. Voluntary delisting would remove the company from Nasdaq, while deregistration would change its ongoing public-company reporting and market structure.
The specific Nasdaq compliance issue and the timing of any delisting or deregistration steps remain open. The next relevant developments are the company’s formal filings, Nasdaq’s timetable and any notice describing how LNAI shares will trade after delisting.
Our read · Thu, Oct 22
LNAI received a Nasdaq compliance notice and plans to voluntarily delist and deregister its securities.
Why. The exchange exit removes Nasdaq’s listing framework from the trading setup, while Lunai’s fiscal-year revenue of $51,992 and -6852.0% net margin show a very small business with substantial reported losses. The next filing and Nasdaq timetable will determine how quickly the listing changes occur and what public-company reporting remains in place.
Both cases
What could change this view: The trade read is invalidated if Lunai remains Nasdaq-listed or reverses the voluntary delisting and deregistration plan.
Who reported it · 1
Keep reading
Latest on the Wire
Democrats flip key Texas, Ohio and South Carolina races in midtermsFutures rebound after blue sweep as dollar slides and gold tops $4,000Trimble reports stronger third quarter and updates full-year outlookCVS Health plans split between pharmacy and insurance businessesStanley Black & Decker raises 2026 guidance after tariff refundsContinue on the Wire →Latest on the Wire
Democratic governors win Texas, Georgia and Ohio on data-center backlashBlock faces proposed $764 million DOJ settlement as bitcoin profit halvesTroy Jackson flips Susan Collins’s Maine Senate seat for DemocratsOracle cancels $7bn Tencent AI deal under Trump pressureContinue on the Wire →Top this week
Binance halts withdrawals after apparent $6.3bn security breachAlphabet cloud revenue doubles as AI threatens search monetizationDemocrats sweep Congress, setting Trump up for legislative gridlockAmazon burns $33.5 billion in free cash flow as capex surgesTrump’s Republican Party faces a midterm verdict from US voters todayAbout this report
Reported by PR Newswire as Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →